MAIA Biotechnology CEO and Director Acquire 147,700 Shares to Signal Confidence
MAIA•MAIA Biotechnology’s CEO purchased 72,700 shares and a director acquired 75,000 shares in open market transactions, increasing insider ownership to 20.46% of outstanding stock. These buys underline executive confidence as the company advances its ateganosine telomere-targeting immuno-oncology program toward later-stage development.
1. Insider Purchases Details
On June 6, 2026, MAIA Biotechnology’s founder and CEO Vlad Vitoc purchased approximately 72,700 shares at an average price of $1.3877, while Director Stan V. Smith acquired about 75,000 shares at $1.336 per share in open market transactions.
2. Insider Ownership and Stake
Following these transactions, directors and officers hold 20.46% of MAIA’s common stock, reflecting sustained executive commitment to the company’s growth and valuation.
3. Program Progress and Strategic Confidence
Executives emphasized their confidence in MAIA’s telomere-targeting immuno-oncology platform as the ateganosine program progresses toward later-stage clinical development for advanced non-small cell lung cancer, positioning the therapy as a potential new standard of care.
